

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT:
James T. Kealey, et al.FILING DATE
November 8, 1999GROUP
1635

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	P1	5,583,016	10 Dec '96	Villeponteau et al.			
	P2	5,770,422	23 Jun '98	Collins			
	P3	5,776,679	07 Jul '98	Villeponteau et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	F1	WO 95/13381	18 May '95	PCT				
	F2	WO 96/01614	25 Jan '96	PCT				
	F3	WO 96/01835	25 Jan '96	PCT				
	F4	WO 96/40868	19 Dec '96	PCT				
	F5							

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

D1	Albanell et al., "Telomerase Activity Is Repressed During Differentiation of Maturation-Sensitive but Not Resistant Human Tumor Cell Lines," <i>Cancer Research</i> , 56:1503-1508 (1996)
D2	Avilion et al., "Human Telomerase RNA and Telomerase Activity in Immortal Cell Lines and Tumor Tissues," <i>Cancer Research</i> , 56:645-650 (1996)
D3	Blasco et al., "Functional Characterization and Developmental Regulation of Mouse Telomerase RNA," <i>Science</i> , 269:1267-1270 (1995)
D4	Bodnar et al., "Mechanism of Telomerase Induction During T Cell Activation," <i>Experimental Cell Research</i> , 228:58-68, Article No. 0299 (1996)

EXAMINER

DATE CONSIDERED

/Terra Cotta Gibbs/

04/25/2009

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PA1 AND TRADEMARK OFFICE	ATTY. DOCKET NO. GERN-008/02US	SERIAL NO. 09/436,060
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: James T. Kealey, et al.	
		FILING DATE November 8, 1999	GROUP 1635

	D5	Branch, <i>TIBS</i> , 23:45-50 (Feb 1998)
	D6	Feng et al., "The RNA Component of Human Telomerase," <i>Science</i> , 269:1236-1241 (1995)
	D7	Gewirtz et al., "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise," <i>PNAS</i> , 93:3161 (Apr 1996)
	D8	Harley et al., "Telomeres and Telomerase in Aging and Cancer," <i>Current Opinion in Genetics and Development</i> , 5:249-255 (1995)
	D9	Hodgson, "Advances in Vector Systems for Gene Therapy," <i>Exp. Opin. Ther. Patents</i> , 5(5):459-468 (1995)
	D10	Kim et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," <i>Science</i> , 266:2011-2015 (1994)
	D11	Rojanasakul et al., "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," <i>Advanced Drug Delivery Reviews</i> , 18:115-131 (1996)
	D12	Villeponteau, "The RNA Components of Human and Mouse Telomerases," <i>Seminars in Cell and Development Biology</i> , 7:15-21 (1996)
	D13	
EXAMINER		/Terra Cotta Gibbs/
		DATE CONSIDERED 04/25/2009

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

485726 v1/PA
@#S#01!.DOC